engages in the development, manufacture, and commercialization of diagnostic imaging and therapeutic products for the detection and treatment of cancer, autoimmune, and other diseases.
The company offers its CEA-Scan, a diagnostic imaging agent used for the detection of colorectal cancers, in the United States and Canada, as well as in Europe.
It offers its LeukoScan, a diagnostic product used for the detection of bone infections, in Europe and Australia.
Immunomedics’ therapeutic product candidates primarily comprised epratuzumab, which completed certain Phase II clinical trials for the treatment of nonHodgkin's lymphoma, as well as labetuzumab, which was in Phase I/II clinical trials for the treatment of certain solid tumors and hematologic malignancies, as of June 30, 2004.
The company was founded by David M.
Goldenberg.
Immunomedics was incorporated in 1982 and is headquartered in Morris Plains, New Jersey.
